|Bid||147.27 x 900|
|Ask||147.56 x 800|
|Day's Range||144.21 - 148.35|
|52 Week Range||117.58 - 212.00|
|Beta (5Y Monthly)||0.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 27, 2022 - May 02, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||208.20|
A little competition can greatly benefit patients. Shareholders may have a more difficult path to navigate.
When Dr. Shehnaaz Suliman joined ReCode Therapeutics Inc. in December as CEO, she knew of the oversubscribed $80 million Series B round the Menlo Park company raised two months before. The Series B extension was co-led by Leaps by Bayer, the venture capital arm of German drug giant Bayer AG, and Matrix Capital Management affiliate AyurMaya with participation from Amgen Ventures. ReCode already plans to file an investigational drug application with the Food and Drug Administration — launching the process of clinical trials — in the fourth quarter for an experimental treatment of primary ciliary dyskinesia and in second-quarter 2023 against cystic fibrosis.
Foreign direct investments play an important role as an indicator of a healthy economy in terms of economic growth and long-term capital movement.